IRIS PubliCatt

Rossetti, Barbara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.184
EU - Europa 977
AS - Asia 346
AF - Africa 24
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 3
Totale 2.544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.159
SE - Svezia 202
IT - Italia 193
FR - Francia 136
CN - Cina 132
PL - Polonia 113
DE - Germania 84
SG - Singapore 69
IN - India 66
IE - Irlanda 62
GB - Regno Unito 43
ID - Indonesia 28
FI - Finlandia 27
RU - Federazione Russa 26
UA - Ucraina 24
ES - Italia 21
MX - Messico 14
KR - Corea 10
PH - Filippine 10
CA - Canada 9
CM - Camerun 8
PT - Portogallo 8
BE - Belgio 7
IR - Iran 7
RO - Romania 7
ZA - Sudafrica 7
HK - Hong Kong 6
GR - Grecia 5
TR - Turchia 5
TW - Taiwan 5
CI - Costa d'Avorio 4
EU - Europa 4
AU - Australia 3
CH - Svizzera 3
CL - Cile 3
NL - Olanda 3
AT - Austria 2
BR - Brasile 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
LT - Lituania 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
HN - Honduras 1
JP - Giappone 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MK - Macedonia 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
PA - Panama 1
PK - Pakistan 1
TN - Tunisia 1
UG - Uganda 1
VN - Vietnam 1
Totale 2.544
Salva come PNG Salva come JPEG
Città #
Chandler 320
Kraków 108
Ashburn 75
New York 72
Dublin 61
Milan 53
Jacksonville 40
Redmond 36
San Mateo 36
Singapore 33
Boston 27
Rome 27
Jakarta 26
Wilmington 26
Princeton 24
Ann Arbor 23
Beijing 22
Marseille 22
Cattolica 21
London 19
Moscow 19
Nanjing 19
Paris 18
Pune 17
Redwood City 17
Dearborn 16
Houston 15
Catania 14
Madrid 12
Helsinki 10
Nanchang 10
Fairfield 9
Los Angeles 9
Norwalk 9
Lawrence 8
Seattle 8
Woodbridge 8
Bremen 7
Changsha 7
Chicago 7
Brussels 6
Cusano Milanino 6
Davao City 6
Hebei 6
Turin 6
Washington 6
Boardman 5
Bucharest 5
La Habra 5
Lancaster 5
Mountain View 5
Shenyang 5
Edinburgh 4
Florence 4
Fuzhou 4
Hangzhou 4
Hefei 4
Jiaxing 4
Kempton Park 4
Lappeenranta 4
Nürnberg 4
Suyeong-gu 4
Tianjin 4
Amsterdam 3
Atlanta 3
Aversa 3
Cambridge 3
Frankfurt am Main 3
Georgetown 3
Guadalupe 3
Hong Kong 3
Kish 3
Kunming 3
Longarone 3
Manchester 3
Seoul 3
Stockholm 3
Surrey 3
Taipei 3
Warsaw 3
Abidjan 2
Andover 2
Angke 2
Ansbach 2
Arcadia 2
Augusta 2
Bangkok 2
Basel 2
Benidorm 2
Bologna 2
Brno 2
Burnaby 2
Charleston 2
Ciudad Nezahualcoyotl 2
Council Bluffs 2
Coyoacán 2
Cuauhtemoc 2
Cupertino 2
Daegu 2
Dallas 2
Totale 1.511
Salva come PNG Salva come JPEG
Nome #
The effects of switching from dolutegravir/abacavir/ lamivudine to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV on neuropsychiatric symptoms: preliminary findings from a randomised study 310
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 136
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 132
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 97
Cognitive reserve and neuropsychological functioning in older HIV-infected people 96
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 91
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 89
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 84
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 81
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 78
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 78
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 73
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 73
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 66
Pretreatment HIV drug resistance and treatment failure in non-Italian HIV-1-infected patients enrolled in ARCA 66
Whole-genome sequencing reveals host factors underlying critical COVID-19 65
Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy 60
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults 55
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 52
Impact of Antiretroviral Therapy on the Risk of Recurrence in HIV-1 Infected Patients with Kaposi Sarcoma: A Multicenter Cohort Experience 52
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 52
First report of spondylodiscitis due to vancomycin heteroresistant Staphylococcus capitis in immunocompetent host 51
Has COVID-19 changed the approach to HIV diagnosis?: A multicentric Italian experience 50
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE) 48
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 48
An explainable model of host genetic interactions linked to COVID-19 severity 47
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study 46
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 46
Treatment of HCV infection with the novel NS3/4A protease inhibitors 43
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort 43
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline VIRO-immunological status and outcome in patients under first-line ART 40
Listeria meningoencephalitis and anti-GQ1b antibody syndrome 33
Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors 33
Impact of pre-existent drug resistance on virological efficacy of single-tablet regimens in people living with HIV 29
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 27
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 26
Dynamics of total and intact HIV-1 DNA in virologically suppressed patients switching to DTG- or ATV-based dual therapy 25
Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study 20
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study 18
Nasopharingeal bacterial and fungal colonization in HIV-positive versus HIV-negative adults 16
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 14
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 6
Totale 2.595
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.861
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.861
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020169 0 0 5 1 14 19 16 2 13 3 88 8
2020/2021106 23 11 4 5 12 8 6 2 13 6 12 4
2021/2022269 12 3 4 19 7 12 13 53 10 27 34 75
2022/2023887 96 105 53 116 61 100 32 77 101 70 58 18
2023/2024567 27 108 28 40 36 126 31 25 24 24 39 59
2024/2025123 30 40 53 0 0 0 0 0 0 0 0 0
Totale 2.595